Ann: Imugene Corporate Presentation, page-213

Some quotes from Leslie (Sydney Presentation)

Leslie Chong

"We have roughly 125 patients across all our studies, some of them are living 3, 4 years on our medicine and have derived a complete response meaning hopefully they will surpass that 5 years for a doctor to consider cure"

"We know for a fact that now, in our patient population that if our virus can get to the tumors it will infect and it will kill that tumour"

"I love the idea of a universal platform for tumor target, you know what that means, we make caner, solid tumor into one disease, and then treat it because right now cancer is thousands, if not hundreds of thousands of different disease, so attacking it is quite difficult so i feel we are very close to that solution"

"Value realisation will be had when we have a company acquisition perhaps or we partner with big pharma, we also licensed our technologies individually"

"Multiple value inflection points, i think that onCARlytics to me, the first patient in is going to cause some noise in the industry because its the first in class and hopefully best in class"

"onCARlytics, we think we have something unique here in that it infects and replicates in any solid tumor"

"In 3 years time i hope to have some of my folks actually working with some our products in pharma companies because they will have to do internships to take in a product, they tend to take in the resources for a little bit to get training and then we hope to form another company, i love doing this, i think this is significant and i love getting up every morning thinking about the patients we are serving, so for me i hope to be doing the same thing but perhaps not imugene but perhaps imugene 2.0"  



In the midst of all the noisy discussions here, I'm keeping my focus on what the company itself is officially saying, and what Leslie has said above, is truely amazing.  

I understand the importance of reliable information, so I'm not paying much attention to the wild stories and unproven rumors circulating, Instead, I'm being careful to only consider updates and announcements that come directly from the company. This way, I can make investment decisions based on real facts and not get distracted by unfounded claims.

Imugene in my opinion is on the verge of greatness, and it's an exciting time for all stakeholders.